MacroGenics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics, including DART molecules and antibody-drug conjugates. Current reports record financial and operating results, FDA-related updates for the LINNET study of lorigerlimab, and material agreements involving ZYNYZ royalty rights under the Incyte collaboration.
Proxy and governance filings cover board elections, executive compensation, director matters and officer transitions. The filing record also addresses capital resources, collaboration and license economics, clinical-development disclosures, product-candidate updates and stockholder voting matters.
MACROGENICS INC (MGNX) has a former officer, Thomas Spitznagel, filing a notice of proposed sale of common stock under Rule 144. The notice covers the potential sale of 15,811 shares of common stock through Merrill Lynch, with an approximate sale date of September 21, 2026 on NASDAQ.
The filing also reports that during the prior three months, Spitznagel sold 17,000 shares of MacroGenics common stock on July 13, 2026.
MacroGenics, Inc. (MGNX) restates its unaudited pro forma financials to treat the June 30, 2026 sale of its CDMO manufacturing operations to Bora as a discontinued operation. The transaction generated $119.6 million in cash at closing and an estimated $91.7 million gain on derecognition of the sold assets.
Pro forma as of March 31, 2026, cash and cash equivalents increase to $177.3 million, and total stockholders’ equity rises to $112.9 million. MacroGenics’ continuing operations now exclude contract manufacturing revenue and related costs, with pro forma 2025 revenue of $96.9 million and a net loss from continuing operations of $91.2 million, or $1.44 per share.
The company describes the divestiture as a strategic shift exiting contract manufacturing to focus resources on its pre-clinical and clinical-stage R&D pipeline. Potential additional contingent payments of up to $5 million are tied to future manufacturing milestones and services and are not reflected in the pro forma figures.
MACROGENICS INC (MGNX) reported that officer Jeffrey Stuart Peters, Senior VP, GC, and Secretary, sold 31,105 shares of common stock on 2026-08-19 in an open-market or private transaction. The sale, effected under a Rule 10b5-1 trading plan adopted on May 20, 2026, was executed in multiple trades at prices ranging from $4.12 to $4.24 per share, with a reported per-share price of $4.15. Following this transaction, Peters reported holding 0 shares of MacroGenics common stock directly.
MACROGENICS INC (MGNX) has a notice of proposed share sales filed under Rule 144 on behalf of officer Jeffrey Peters. The filing lists multiple blocks of common stock acquired through “stock plan activity” on dates in 2025 and 2026 that may be sold through Merrill Lynch on NASDAQ after the Rule 144 conditions are met.
MACROGENICS INC (MGNX) reported that Sr VP, Research & CSO Ezio Bonvini40,000 shares at $2.60 per share on 2026-08-17. This option exercise converted into 40,000 shares of Common Stock in an exercise-and-hold transaction. Following the transaction, Bonvini directly holds 185,799 shares of Common Stock and 88,000 Employee Stock Options with an exercise price of $2.60 per share expiring on 2035-02-07. Footnotes indicate a staggered vesting schedule for the option grant.
MacroGenics, Inc. (symbol MGNX) has a notice of proposed resale of its common stock under Form 144. The filing lists 42,080 shares of common stock to be sold through Merrill Lynch, with a proposed sale date of 08/17/2026 on NASDAQ.
The seller is identified as Jay Siegel, with a section also listing securities sold during the past 3 months: on 08/03/2026, a transaction in common stock for 34,916 shares is reported, alongside a related value of 130,905. Another numeric identifier 63,700,187 appears in the securities information section.
MacroGenics, Inc. reported sharply higher revenue and a headline profit for the quarter ended June 30, 2026, driven by collaboration milestones, rising royalties and a large gain from divesting its contract development and manufacturing operations (CDMO Operations) to Bora for cash consideration of approximately $119.6 million. Total revenues from continuing operations were $32.8 million in the quarter and $39.6 million for the first half of 2026, up significantly from 2025, aided by $24.5 million in regulatory milestone revenue from Sanofi and higher ZYNYZ royalty revenue.
The company remains loss-making in its core business, with a net loss from continuing operations of $69.6 million in Q2 and $110.9 million year‑to‑date, including a $52.8 million non‑cash loss on extinguishment of its original ZYNYZ royalty monetization liability after amending the Sagard arrangement, which increased the related liability to $178.1 million. However, the gain on sale of the CDMO Operations of $86.1 million produced net income of $19.5 million for the quarter.
Cash and cash equivalents were $113.9 million and marketable securities $59.4 million at June 30, 2026. Management states that existing cash and investments, together with Bora proceeds, the Sanofi milestone and a $10.0 million option payment from Gilead, support the company’s cash runway through 2028, while it continues to fund multiple oncology antibody and ADC programs and implements cost‑saving measures.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of common stock of MacroGenics, Inc. as of June 30, 2026. They disclose beneficial ownership of 5,006,752 shares of MacroGenics common stock, representing 7.88% of the outstanding class.
Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd., and Steven Boyd, as its managing member, each report shared voting and dispositive power over all 5,006,752 shares and no sole voting or dispositive power. The Master Fund, a Cayman Islands exempted company, is entitled to receive dividends and sale proceeds from these securities.
MacroGenics, Inc. reported second quarter 2026 results and a major strategic shift to a fully outsourced manufacturing model. The company completed the sale of its GMP drug substance manufacturing operations to Bora for a base purchase price of $122.5 million, receiving $119.6 million in cash at closing and reducing its workforce toward approximately 140 employees while entering a long-term supply agreement with Bora.
Pro forma cash, cash equivalents and marketable securities totaled $327 million as of June 30, 2026, supporting a stated cash runway through 2028. Quarterly revenue rose to $32.8 million, mainly from a $24.5 million Sanofi milestone, and net income was $19.5 million versus a prior-year loss, driven by $89.2 million income from discontinued operations and partly offset by a $52.8 million non-cash loss on extinguishment of a ZYNYZ royalty monetization liability. The pipeline advanced with Phase 1 progress for MGC026, ongoing studies for MGC028 and lorigerlimab, IND clearance for MGC030, and nomination of preclinical TCE MGD032, while the company remains eligible for up to approximately $2.4 billion in future milestones from partners.
MGNX has a notice covering a planned sale of common stock under Rule 144. A holder intends to sell up to 20,166 shares of common stock through Merrill Lynch, with a proposed sale date of 08/03/2026 on the NASDAQ. The shares were obtained via stock plan activity on several dates, including 05/20/2024, 05/20/2025, and 05/18/2026.